HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
Recursion (NASDAQ: RXRX) has partnered with HealthVerity to enhance its clinical trial capabilities through real-world data integration. The collaboration will give Recursion access to de-identified data covering over 340M lives in the US, which will be integrated into their Recursion OS platform.
This strategic partnership aims to improve clinical trial design, patient population insights, and trial feasibility assessments. Recursion will leverage HealthVerity's comprehensive healthcare data ecosystem to enhance their AI-driven approach, predict patient responses, and optimize study designs while ensuring regulatory compliance.
The integration of HealthVerity's real-world data into Recursion's platforms is expected to streamline clinical development, reduce costs, and accelerate the development of novel therapeutics while maintaining HIPAA compliance and patient privacy standards.
Recursion (NASDAQ: RXRX) ha stretto una collaborazione con HealthVerity per potenziare le sue capacità nei trial clinici grazie all'integrazione di dati real-world. Questa partnership permetterà a Recursion di accedere a dati de-identificati che coprono oltre 340 milioni di persone negli Stati Uniti, integrandoli nella loro piattaforma Recursion OS.
Questa collaborazione strategica mira a migliorare la progettazione dei trial clinici, la comprensione delle popolazioni di pazienti e la valutazione della fattibilità degli studi. Recursion sfrutterà l'ampio ecosistema di dati sanitari di HealthVerity per potenziare il suo approccio basato sull'intelligenza artificiale, prevedere le risposte dei pazienti e ottimizzare i disegni degli studi, garantendo al contempo la conformità normativa.
L'integrazione dei dati real-world di HealthVerity nelle piattaforme di Recursion dovrebbe semplificare lo sviluppo clinico, ridurre i costi e accelerare la creazione di nuove terapie, mantenendo la conformità con HIPAA e gli standard di privacy dei pazienti.
Recursion (NASDAQ: RXRX) se ha asociado con HealthVerity para mejorar sus capacidades en ensayos clínicos mediante la integración de datos del mundo real. Esta colaboración dará a Recursion acceso a datos desidentificados que cubren a más de 340 millones de personas en Estados Unidos, los cuales serán integrados en su plataforma Recursion OS.
Esta alianza estratégica busca mejorar el diseño de ensayos clínicos, el conocimiento de las poblaciones de pacientes y la evaluación de la viabilidad de los estudios. Recursion aprovechará el completo ecosistema de datos de salud de HealthVerity para potenciar su enfoque impulsado por IA, predecir las respuestas de los pacientes y optimizar los diseños de los estudios, asegurando el cumplimiento normativo.
Se espera que la integración de los datos del mundo real de HealthVerity en las plataformas de Recursion agilice el desarrollo clínico, reduzca costos y acelere la creación de nuevos tratamientos, manteniendo la conformidad con HIPAA y los estándares de privacidad del paciente.
Recursion (NASDAQ: RXRX)는 HealthVerity와 협력하여 실제 데이터 통합을 통해 임상 시험 역량을 강화합니다. 이번 협력으로 Recursion은 미국 내 3억 4천만 명 이상의 비식별화된 데이터를 Recursion OS 플랫폼에 통합할 수 있게 됩니다.
이 전략적 파트너십은 임상 시험 설계, 환자 집단 인사이트, 시험 타당성 평가를 향상시키는 것을 목표로 합니다. Recursion은 HealthVerity의 포괄적인 헬스케어 데이터 생태계를 활용하여 AI 기반 접근법을 강화하고, 환자 반응을 예측하며, 연구 설계를 최적화하는 동시에 규제 준수를 보장할 것입니다.
HealthVerity의 실제 데이터가 Recursion 플랫폼에 통합되면 임상 개발이 간소화되고 비용이 절감되며, 새로운 치료제 개발이 가속화될 것으로 기대되며, HIPAA 준수 및 환자 개인정보 보호 기준도 유지됩니다.
Recursion (NASDAQ : RXRX) s'est associé à HealthVerity pour renforcer ses capacités dans les essais cliniques grâce à l'intégration de données du monde réel. Cette collaboration donnera à Recursion accès à des données dé-identifiées couvrant plus de 340 millions de personnes aux États-Unis, qui seront intégrées à leur plateforme Recursion OS.
Ce partenariat stratégique vise à améliorer la conception des essais cliniques, la compréhension des populations de patients et l'évaluation de la faisabilité des études. Recursion exploitera l'écosystème complet de données de santé de HealthVerity pour renforcer son approche basée sur l'IA, prédire les réponses des patients et optimiser les protocoles d'étude tout en assurant la conformité réglementaire.
L'intégration des données du monde réel de HealthVerity dans les plateformes de Recursion devrait faciliter le développement clinique, réduire les coûts et accélérer la mise au point de nouveaux traitements, tout en respectant la conformité HIPAA et les normes de confidentialité des patients.
Recursion (NASDAQ: RXRX) hat eine Partnerschaft mit HealthVerity geschlossen, um seine Fähigkeiten bei klinischen Studien durch die Integration von Real-World-Daten zu verbessern. Die Zusammenarbeit ermöglicht Recursion den Zugriff auf anonymisierte Daten von über 340 Millionen Menschen in den USA, die in ihre Recursion OS-Plattform integriert werden.
Diese strategische Partnerschaft zielt darauf ab, das Design klinischer Studien, Erkenntnisse über Patientengruppen und die Machbarkeitsbewertung von Studien zu verbessern. Recursion wird das umfassende Gesundheitsdaten-Ökosystem von HealthVerity nutzen, um ihren KI-gesteuerten Ansatz zu optimieren, Patientenreaktionen vorherzusagen und Studiendesigns zu verbessern, während die Einhaltung gesetzlicher Vorschriften sichergestellt wird.
Die Integration der Real-World-Daten von HealthVerity in die Plattformen von Recursion soll die klinische Entwicklung vereinfachen, Kosten senken und die Entwicklung neuer Therapien beschleunigen, wobei HIPAA-Konformität und Datenschutzstandards gewahrt bleiben.
- Access to extensive healthcare data covering 340M lives enhances clinical trial capabilities
- Integration with Recursion OS platform could reduce clinical development costs
- Partnership enables improved trial design and patient recruitment efficiency
- Enhanced ability to predict patient responses and optimize study designs
- None.
Insights
Recursion's new partnership with HealthVerity represents a strategic enhancement to their clinical development capabilities. By licensing real-world data covering
The integration of this extensive dataset into Recursion's OS platform could deliver three key benefits: (1) more efficient trial design through improved patient population insights, (2) accelerated recruitment by leveraging data for site selection and enrollment strategies, and (3) enhanced evidence generation for regulatory submissions.
For a clinical-stage TechBio company like Recursion, whose competitive advantage lies in its computational approach to drug discovery, this data enrichment directly strengthens their core technology infrastructure. The partnership potentially addresses critical bottlenecks in clinical development by allowing for better in silico simulations and patient-centric recruitment approaches.
While financial terms weren't disclosed, this type of data licensing agreement typically represents a manageable expense relative to the potential efficiency gains in clinical operations. For Recursion, whose approach depends on integrating diverse datasets with AI/ML models, this additional data layer should enhance their predictive capabilities across their pipeline development efforts.
This partnership aligns with Recursion's broader strategy of using computational tools to industrialize drug development and potentially reduce the time and cost required to bring therapies to market.
Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.
"Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials," said Andrew Kress, CEO of HealthVerity. "By providing seamless access to the industry's most comprehensive and interoperable real-world data, we empower innovators like Recursion to make data-driven decisions that streamline clinical development."
Recursion's proprietary AI-driven approach relies on integrating diverse datasets and AI/ML models to identify novel insights into human biology and molecule design. The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites are positioned to meet enrollment goals.
"With the majority of the industry's time and resources focused on clinical trials, we see a significant opportunity to transform how clinical development is designed and executed," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. "By integrating privacy-compliant real-world data from HealthVerity into Recursion OS, we are advancing our mission to optimize trial design through in silico simulations, accelerate recruitment through a patient-centric approach that includes underserved populations, and generate stronger evidence to inform development and regulatory decisions. By doing so, we are not only streamlining clinical development but also ensuring that we bring more impactful, life-changing treatments to patients faster and more efficiently"
The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks while maintaining the highest standards of patient privacy. By combining data from the nation's largest healthcare data ecosystem, HealthVerity enables precise patient journey insights, supporting clinical development, regulatory submissions, and post-market studies.
For more information, visit www.healthverity.com.
About HealthVerity
HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.
Media Contact:
HealthVerity
info@healthverity.com
Recursion
media@recursion.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/healthverity-partners-with-recursion-to-enhance-clinical-trial-analytics-with-real-world-data-302429759.html
SOURCE HealthVerity, Inc.
FAQ
What is the scope of HealthVerity's data access provided to Recursion (RXRX)?
How will Recursion (RXRX) use HealthVerity's real-world data in clinical trials?
What are the expected benefits of the Recursion-HealthVerity partnership for RXRX's clinical development?
How does the HealthVerity partnership enhance Recursion's (RXRX) existing technology platform?
